We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App





PerkinElmer Demonstrates High-Throughput MSMS Dried Blood Spot Screening Solutions at Medlab Middle East 2021

By LabMedica International staff writers
Posted on 21 Jun 2021
PerkinElmer, Inc. More...
(Waltham, MA; USA) demonstrated its high-throughput MSMS dried blood spot screening solutions at the 2021 edition of Medlab Middle East, the leading medical laboratory exhibition in the region for over 20 years.

On display at the event was the PerkinElmer QSight 225 LC/MS/MS system developed uniquely for newborn screening with the option for tier 2 testing – using just a single heel-prick dried blood spot (DBS) card. The QSight system delivers a unique combination of self-cleaning MS/MS instrumentation that provides exceptional system uptime, a simple setup process, and easy-to-use database software that simplifies review and analysis - plus kits and reagents, training, and support. The QSight system includes a high capacity autosampler, precision binary pump, best in class MS detector, and easy to use instrument control and data analysis software that have been optimized to run hundreds of samples per day, for weeks at a time, to generate consistent results with minimum maintenance or downtime.

PerkinElmer also exhibited the Opera Phenix High Content Screening System, the premier confocal solution for today's most demanding high content applications. Drawing on over a decade of experience with the industry-leading Opera High Content Screening System, the Opera Phenix is designed for high-throughput, phenotypic screening and assays involving complex disease models, such as live cells, primary cells and microtissues. In addition, PerkinElmer highlighted the VICTOR Nivo multimode reader that breaks new ground, packing all popular detection modes into the industry’s smallest benchtop footprint. The successor to the highly popular VICTOR X system - the world’s first multimode plate reader - the VICTOR Nivo system detects absorbance, luminescence, fluorescence intensity, time-resolved fluorescence, fluorescence polarization and now Alpha technologies, making it perfect for everyday biochemical and cell-based assays, including kinetic measurements.

At this year’s Medlab Middle East, PerkinElmer displayed the LC 300 chromatography platform that redefines and simplifies LC, delivering the flexibility, performance, and efficiency to tackle challenging analytical demands. Users can choose between a 10k-psi system for HPLC and an 18k-psi system for ultraprecise UHPLC analysis. Both offer patented valve technology and sample handling options to accommodate multiple sample tray formats. And SimplicityChrom 21CFR11 software delivers intuitive instrument control, while an integrated color display shows immediate system status. Combined with CDS third-party drivers for commercial systems, this offers a powerful and simple LC solution. Also on display was the chemagic 360 instrument, with dimensions of only 80 x 80 cm and its unique sample volume flexibility, making it the ideal solution for nucleic acid isolation in human genetics, biobanking, HLA typing, viral and bacterial detection.

Related Links:
PerkinElmer, Inc.


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
PSA Test
Humasis PSA Card
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.